Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Diseases of the central nervous system caused by prions

INTRODUCTION

Prion diseases are neurodegenerative diseases that have long incubation periods and progress inexorably once clinical symptoms appear. Five human prion diseases are currently recognized: kuru, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD also known as new variant CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI) [1,2]. Bovine spongiform encephalopathy (BSE), one of a number of prion infections affecting animals, was responsible for bringing these agents to more widespread public attention with its possible link to vCJD [3,4].

These human prion diseases share certain common neuropathologic features including neuronal loss, proliferation of glial cells, absence of an inflammatory response, and the presence of small vacuoles within the neuropil, which produces a spongiform appearance. The current theory is that prion diseases are associated with the accumulation of an abnormal form of a host cell protein, the normal form is designated PrPc, and the abnormal form is designated PrPSc (for Scrapie) [5].

The clinical manifestations and diagnosis of the prion diseases Kuru, GSS, and FFI will be reviewed here. CJD and variant CJD are discussed separately. (See "Creutzfeldt-Jakob disease" and "Variant Creutzfeldt-Jakob disease".)

The biology of prions and the genetics of prion diseases are discussed separately. (See "Biology and genetics of prions".)

KURU

Kuru was the first transmissible neurodegenerative disease to be identified and well studied; it has served as the prototype of human prion diseases [6,7].

                      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Oct 17, 2011.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med 1997; 337:1821.
  2. Prusiner SB. Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med 2001; 344:1516.
  3. O'Brien C. Mad cow disease. Scant data cause widespread concern. Science 1996; 271:1798.
  4. Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999; 354:317.
  5. Prusiner SB. The prion hypothesis. In: Prions, Prusiner, SB, McKinley, MP (Eds), Academic Press, San Diego 1987. p.17.
  6. GAJDUSEK DC, ZIGAS V. Degenerative disease of the central nervous system in New Guinea; the endemic occurrence of kuru in the native population. N Engl J Med 1957; 257:974.
  7. Prusiner SB, Gajdusek C, Alpers MP. Kuru with incubation periods exceeding two decades. Ann Neurol 1982; 12:1.
  8. Gajdusek DC. Infectious amyloids: Subacute spongiform encephalopathies as transmissible cerebral amyloidoses. In: Fields Virology, 3rd, Fields, BN, Knipe, DM, Howley, PM (Eds), Lippincott-Raven, New York 1996. p.2851.
  9. Collinge J, Whitfield J, McKintosh E, et al. Kuru in the 21st century--an acquired human prion disease with very long incubation periods. Lancet 2006; 367:2068.
  10. Cobb WA, Hornabrook RW, Sanders S. The EEG of kuru. Electroencephalogr Clin Neurophysiol 1973; 34:419.
  11. Hainfellner JA, Liberski PP, Guiroy DC, et al. Pathology and immunocytochemistry of a kuru brain. Brain Pathol 1997; 7:547.
  12. Mead S, Whitfield J, Poulter M, et al. A novel protective prion protein variant that colocalizes with kuru exposure. N Engl J Med 2009; 361:2056.
  13. Brown P, Goldfarb LG, Brown WT, et al. Clinical and molecular genetic study of a large German kindred with Gerstmann-Sträussler-Scheinker syndrome. Neurology 1991; 41:375.
  14. Ghetti B, Dlouhy SR, Giaccone G, et al. Gerstmann-Sträussler-Scheinker disease and the Indiana kindred. Brain Pathol 1995; 5:61.
  15. Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998; 339:1994.
  16. Webb TE, Poulter M, Beck J, et al. Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain 2008; 131:2632.
  17. Arata H, Takashima H, Hirano R, et al. Early clinical signs and imaging findings in Gerstmann-Sträussler-Scheinker syndrome (Pro102Leu). Neurology 2006; 66:1672.
  18. Unverzagt FW, Farlow MR, Norton J, et al. Neuropsychological function in patients with Gerstmann-Sträussler-Scheinker disease from the Indiana kindred (F198S). J Int Neuropsychol Soc 1997; 3:169.
  19. Lyketsos CG, Kraus M. The dementia of Gerstmann-Sträussler-Scheinker syndrome: clinical variability demonstrated by two case reports. J Neuropsychiatry Clin Neurosci 1995; 7:239.
  20. Jansen C, Voet W, Head MW, et al. A novel seven-octapeptide repeat insertion in the prion protein gene (PRNP) in a Dutch pedigree with Gerstmann-Sträussler-Scheinker disease phenotype: comparison with similar cases from the literature. Acta Neuropathol 2011; 121:59.
  21. Wimberger D, Uranitsch K, Schindler E, Kramer J. Gerstmann-Sträussler-Scheinker syndrome: MR findings. J Comput Assist Tomogr 1993; 17:326.
  22. Guiroy DC, Wakayama I, Liberski PP, Gajdusek DC. Relationship of microglia and scrapie amyloid-immunoreactive plaques in kuru, Creutzfeldt-Jakob disease and Gerstmann-Sträussler syndrome. Acta Neuropathol 1994; 87:526.
  23. Collins S, McLean CA, Masters CL. Gerstmann-Sträussler-Scheinker syndrome,fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies. J Clin Neurosci 2001; 8:387.
  24. Mehta LR, Huddleston BJ, Skalabrin EJ, et al. Sporadic fatal insomnia masquerading as a paraneoplastic cerebellar syndrome. Arch Neurol 2008; 65:971.
  25. Mastrianni JA, Nixon R, Layzer R, et al. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med 1999; 340:1630.
  26. Parchi P, Capellari S, Chin S, et al. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology 1999; 52:1757.
  27. Manetto V, Medori R, Cortelli P, et al. Fatal familial insomnia: clinical and pathologic study of five new cases. Neurology 1992; 42:312.
  28. Krasnianski A, Bartl M, Sanchez Juan PJ, et al. Fatal familial insomnia: Clinical features and early identification. Ann Neurol 2008; 63:658.
  29. Plazzi G, Schutz Y, Cortelli P, et al. Motor overactivity and loss of motor circadian rhythm in fatal familial insomnia: an actigraphic study. Sleep 1997; 20:739.
  30. Gallassi R, Morreale A, Montagna P, et al. "Fatal familial insomnia": neuropsychological study of a disease with thalamic degeneration. Cortex 1992; 28:175.
  31. Medori R, Tritschler HJ, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med 1992; 326:444.
  32. Lugaresi E, Medori R, Montagna P, et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med 1986; 315:997.
  33. Zerr I, Giese A, Windl O, et al. Phenotypic variability in fatal familial insomnia (D178N-129M) genotype. Neurology 1998; 51:1398.
  34. Perani D, Cortelli P, Lucignani G, et al. [18F]FDG PET in fatal familial insomnia: the functional effects of thalamic lesions. Neurology 1993; 43:2565.
  35. Cortelli P, Perani D, Parchi P, et al. Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein. Neurology 1997; 49:126.
  36. Cortelli P, Perani D, Montagna P, et al. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain 2006; 129:668.
  37. Brown P, Kenney K, Little B, et al. Intracerebral distribution of infectious amyloid protein in spongiform encephalopathy. Ann Neurol 1995; 38:245.
  38. Gambetti P, Dong Z, Yuan J, et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 2008; 63:697.
  39. Jansen C, Head MW, van Gool WA, et al. The first case of protease-sensitive prionopathy (PSPr) in The Netherlands: a patient with an unusual GSS-like clinical phenotype. J Neurol Neurosurg Psychiatry 2010; 81:1052.
  40. Zou WQ, Puoti G, Xiao X, et al. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol 2010; 68:162.
  41. Jayadev S, Nochlin D, Poorkaj P, et al. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol 2011; 69:712.
  42. Kumar N, Boeve BF, Boot BP, et al. Clinical characterization of a kindred with a novel 12-octapeptide repeat insertion in the prion protein gene. Arch Neurol 2011; 68:1165.
  43. Stewart LA, Rydzewska LH, Keogh GF, Knight RS. Systematic review of therapeutic interventions in human prion disease. Neurology 2008; 70:1272.
  44. Sanders WL, Dunn TL. Creutzfeldt-Jakob disease treated with amantidine. A report of two cases. J Neurol Neurosurg Psychiatry 1973; 36:581.
  45. Furlow TW Jr, Whitley RJ, Wilmes FJ. Repeated suppression of Creutzfeldt-Jakob disease with vidarabine. Lancet 1982; 2:564.
  46. Villa G, Caltagirone C, Macchi G. Unusual clinical course in a case of Creutzfeldt-Jakob disease. Ital J Neurol Sci 1982; 3:155.
  47. David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir. Lancet 1984; 1:512.
  48. Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt-Jakob disease. Br Med J 1980; 280:902.
  49. Masullo C, Macchi G, Xi YG, Pocchiari M. Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J Infect Dis 1992; 165:784.
  50. Adjou KT, Demaimay R, Deslys JP, et al. MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J Gen Virol 1999; 80 ( Pt 4):1079.
  51. Beringue V, Lasmézas CI, Adjou KT, et al. Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice. J Gen Virol 1999; 80 ( Pt 7):1873.
  52. Caspi S, Halimi M, Yanai A, et al. The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 1998; 273:3484.
  53. Sigurdsson EM, Brown DR, Alim MA, et al. Copper chelation delays the onset of prion disease. J Biol Chem 2003; 278:46199.
  54. Perovic S, Schröder HC, Pergande G, et al. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997; 147:518.
  55. Müller WE, Romero FJ, Perovic S, et al. Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. J Neurochem 1997; 68:2371.
  56. Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006; 63:497.
  57. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 2004; 62:714.
  58. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001; 98:9836.
  59. Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52:503.
  60. Doh-ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004; 78:4999.
  61. Haïk S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004; 63:2413.
  62. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8:334.
  63. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006; 129:2241.
  64. Soto C, Kascsak RJ, Saborío GP, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000; 355:192.
  65. Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003; 302:871.
  66. Paramithiotis E, Pinard M, Lawton T, et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 2003; 9:893.
  67. Sadowski MJ, Pankiewicz J, Prelli F, et al. Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis 2009; 34:267.
  68. White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422:80.
  69. Gilch S, Schätzl HM. Aptamers against prion proteins and prions. Cell Mol Life Sci 2009; 66:2445.
  70. Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 2008; 16:481.
  71. Bertsch U, Winklhofer KF, Hirschberger T, et al. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 2005; 79:7785.